On August 18, SKB BIO rose 3.25% in regular trading, trading at 540.0 HKD/share, with turnover of HKD 143 million. The move was driven by the company's interim results released on August 17, which showed a significant turnaround from loss to profit.

According to the filing, SKB BIO reported H1 revenue of 978.3 million yuan, up 2.9% year-over-year, with gross profit of 737 million yuan, up 11.7%. Net profit attributable to shareholders reached 388 million yuan, compared with a loss of 145.2 million yuan in the year-ago period, representing a full swing to profitability. Earnings per share stood at 1.6639 yuan versus a prior-year loss per share of 0.6371 yuan.

The performance improvement was primarily attributed to the company's strategic transition from an R&D-focused biotech to a full-chain biopharma. Its core product, TROP2 ADC sacituzumab tirumotecan, has now received approval for four indications in China, with multiple registrational clinical studies continuing to advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)